🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Dolutegravir film-coated tablets

Found 24 matching trials

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

PHASE1

This is open label, phase 1 clinical study to evaluate the safety, tolerabi...

Status

Completed

Location

Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital"

Start Date

2018-10-01

Trial ID

NCT03706898

Treatments Being Tested

Elpida®Dolutegravir Sofosbuvir Daclatasvir

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

PHASE1

Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with o...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-05

Trial ID

NCT02738931

Treatments Being Tested

Dolutegravir 50 mg tablet Lamivudine 300 mg tablet Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

PHASE3

This study will compare safety, efficacy, and tolerability of a two drug re...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-18

Trial ID

NCT02831764

Treatments Being Tested

Dolutegravir (DTG)Lamivudine (3TC)Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

PHASE3

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolu...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-06

Trial ID

NCT03016533

Treatments Being Tested

Dolutegravir film-coated tablets Dolutegravir film-coated dispersible tablets ABC/DTG/3TC immediate release tablets ABC/DTG/3TC film-coated dispersible tablets

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

PHASE1

Treatment of human immunodeficiency virus (HIV) infection requires daily or...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-02

Trial ID

NCT02373930

Treatments Being Tested

DTG 50 mg RPV 25 mg DTG/RPV 50 mg/25 mg: Product Code AS DTG/RPV 50 mg/25 mg: Product Code AM DTG/RPV 50 mg/25 mg: Product Code AQ DTG/RPV 50 mg/25 mg: Product Code AK DTG/RPV 50 mg/25 mg: Product Code AR

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

PHASE1

This study is designed to estimate the two-way drug interaction between DCV...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-03

Trial ID

NCT02082808

Treatments Being Tested

DTG DCV

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

PHASE1

Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. Th...

Status

Completed

Location

University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program (Site ID: 4601)

Start Date

2011-04-20

Trial ID

NCT01302847

Treatments Being Tested

DTG film-coated tablets DTG granules for suspension DTG dispersible tablets DTG dispersible tablets DTG dispersible tablets

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

PHASE3

The First Long-Acting Injectable Regimen (FLAIR) study is being conducted t...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2016-10-27

Trial ID

NCT02938520

Treatments Being Tested

Cabotegravir (CAB) tablet Rilpivirine (RPV) tablet Cabotegravir - Injectable Suspension (CAB LA)Rilpivirine - Injectable Suspension (RPV LA)ABC/DTG/3TC STR - Tablet DTG Tablet

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

PHASE1

This is an open-label, randomized, crossover study in healthy adult subject...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-09-01

Trial ID

NCT02893488

Treatments Being Tested

DTG/ABC/3TC FDC DISPERSIBLE TABLET EPZICOM (ABC/3TC)TIVICAY (DTG)

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

EARLY_PHASE1

This is a single-center, open label study to identify adherence levels of c...

Status

Completed

Location

HIV/AIDS Clinical Research Unit / University of Pittsburgh

Start Date

2020-08-31

Trial ID

NCT04302896

Treatments Being Tested

dolutegravir oral tablet 50mg emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg tenofovir disoproxil fumarate oral tablet 300mg lamivudine oral tablet 300mg

Previous Next